Trial Profile

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir/lamivudine (Primary) ; Tenofovir alafenamide
Indications HIV infections; HIV-1 infections
Focus Pharmacodynamics
Acronyms ReNew

Most Recent Events

10 Mar 2021 Status changed from not yet recruiting to withdrawn prior to enrolment because it was withdrawn by drug manufacturer.
04 Apr 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
04 Apr 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com